Philip Curman

Risk of psoriasis in patients treated with dupilumab for bullous pemphigoid: A cohort study

The data underlying this article were provided by TriNetX under licence and by permission. Data sharing upon request to TriNetX via the corresponding author.

Immune-checkpoint inhibitor-induced bullous pemphigoid in patients with metastatic renal cell carcinoma: two case reports and systematic review of the literature

BACKGROUND AND PURPOSE: Immune-checkpoint inhibitors (ICIs) improve outcomes in renal cell carcinoma (RCC) but may cause immune-related adverse events (irAEs), including cutaneous toxicity. Bullous pemphigoid (BP) is a rare but clinically significant irAE that can require ICI dis...

Incident psoriasis in atopic dermatitis: a large-scale cohort study of disease- and treatment-associated risks

Abstract Background Clinical and genetic evidence on the association between atopic dermatitis (AD) and subsequent psoriasis remains conflicting, and it is unclear whether this risk is modified by systemic treatments. Recent reports suggest type 2-targeted biologics may unmask ps...